BMO Capital raised the firm’s price target on Regeneron to $1,025 from $1,001 and keeps an Outperform rating on the shares. The firm is "optimistic" going into the company’s phase 3 BOREAS Dupixent readout for patients with moderate-to-severe COPD that is expected in late March or April though investor expectations are mixed – positive given existing data and approval in asthma and negative given previous failures of biologics in COPD and lack of early data, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on REGN:
- Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease
- Regeneron price target raised to $806 from $787 at RBC Capital
- Regeneron, Sanofi announces FDA acceptance for review of Dupixent sBLA
- Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
- Cantor Fitzgerald biotech analyst to hold analyst/industry conference call